A growing appreciation that cooperation and competition can coexist is transforming the life-sciences innovation landscape. Development was once shrouded in secrecy, but now organizations are coming together.
Straight paths of old
Historically, life-sciences partnerships were linear and closed in nature. The conception, development and delivery of therapies was handled separately — the involvement of one partner ending as that of another began.
This arrangement had its advantages. Risk and reward increased as the drug moved down the chain. But the lack of dialogue with the wider community could often result in costly duplications of effort.
The number of drugs approved by the US Food and Drug Administration (FDA) per billion US dollars spent on research and development (R&D) has halved roughly every 9 years since 1950 — seemingly the opposite of Moore’s law (Gordon Moore, co-founder of technology company Intel, observed that the number of transistors that can be placed, inexpensively, on an integrated circuit doubles every 18–24 months)2. In an effort to defy ‘Eroom’s law’, organizations have been forced to search for ways to boost returns on investment.
Increasing R&D costs and competition from drugs that are no longer covered by patents have squeezed the margins of the conventional linear innovation model.
As researchers better understand the biological complexity of targeted diseases, and the technological complexity of drug discovery and the size of data sets increase, organizations are becoming more reliant on outside expertise.
A conventional closed model of innovation is unsuitable for some medical needs, such as the development of antimalarials or Ebola vaccines.
A growing movement
In response to the limitations of the closed model of innovation, a growing number of organizations have come together over the past two decades to share ideas, data and tools with each other, and often with the wider community.
Open to interpretation
According to Google’s Ngram Viewer, which shows the relative frequency with which certain words and phrases are published, the phrase ‘open innovation’ gained prominence in the English language in 2003 — the year that business specialist Henry Chesbrough, now at the University of California, Berkeley, used it to describe the concept that companies should use external ideas as well as internal ones to advance their technology. But open innovation is just one of the terms that seeks to capture different, but overlapping, themes of openness in the broader innovation ecosystem.
Pioneered by the software-development industry, open-source projects make the fruits of open collaboration free to everyone, with little or no direct profit for the collaborators.
The Open Data Institute in London describes open data as data that anyone can access, use and share.
Open access was a major shake up to the conventional publishing model. Literature is digital, online, free at the point of use and usually free to reproduce in some form.
Open science is the practice of science such that others can contribute. Lab notes are freely available, and the research and its underlying methods can be shared.
Degrees of openness
Whether or not a collaboration qualifies as an example of open innovation can be subjective, but criteria (pictured)3 devised by the Wellcome Trust in London can be used to categorize collaborations. It is generally agreed that the ideal open initiative would be a broad collaboration with public participation through all stages of innovative development, resulting in an output that is free to all.
Sources: 1. Tufts Center for the Study of Drug Development; 2. J. W. Scannell et al. Nature Rev. Drug Discov. 11, 191–200 (2012); 3. R. Pigott et al. Shaping the Future of Open Innovation (Wellcome Trust, CASMI & Kinapse, 2014).Footnote 1
This article is part of the Nature Outlook: Open innovation
Related links in Nature Research
Diagnosing the decline in pharmaceutical R&D efficiency
New drugs cost US.6 billion to develop
Nature Outlook: Open Innovation
Related external links
Division of Signal Transduction Therapy
Structural Genomics Consortium
Rights and permissions
About this article
Cite this article
Holmes, D. A new chapter in innovation. Nature 533, S54–S55 (2016). https://doi.org/10.1038/533S54a
This article is cited by
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
Pharmaceutical Medicine (2019)
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine (2018)